It's no secret that respiratory drugs make up a crowded field, and forthcoming generics will make the competition tougher still. AstraZeneca's Symbicort is no stranger to the fallout, either, what with payers pressing prices and new rivals grabbing share.
South Korean pharmaceutical firm Hanmi Pharmaceutical is expected to cease development of Olita, a lung cancer treatment, following its slow progress in clinical trials and cancellation of licensing deals with foreign drug makers.
Following a successful nine-month pilot, Boehringer Ingelheim and HealthPrize Technologies announced that the digital adherence support program RespiPoints will be expanded to any patient who is taking certain Boehringer Ingelheim medications, including some available in the Respimat inhaler.
Silvia Pfeiffer started Coviu with CSIRO colleague Nathan Oehlman in 2015, and it is now in use by 1100 healthcare professionals, with 160 of them paid subscribers to the software-as-a-service platform at $20 a month. More than 20,000 patients have been remotely consulted to date via the platform, which is browser-based and does not require a download.
NHS Digital’s sharing of non-clinical patient information with the Home Office has been branded “entirely inappropriate” by MPs, who say they are concerned about the body’s ability to act as a reliable steward of the data.
The FDA confirmed in a March 16, 2012 communication released to Bloomberg News that the vaginally placed pelvic mesh product known as the Prolift, sold by Johnson & Johnson subsidiary Ethicon, Inc. since March, 2005, was initially marketed without any clearance or approval from the FDA.
Oxygen supply device maker Inogen Inc said on Friday it was notifying 30,000 existing and former customers following a data breach that led to improper access of personal details of some rental clients.
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.